Regeneron Pharmaceuticals' Cash from Investing Activities fell 3716.49% to $220.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$629.1 million, marking a year-over-year increase of 7451.08%. This contributed to the annual value of -$629.1 million for FY2025, which is 7451.08% up from last year.
Regeneron Pharmaceuticals' Cash from Investing Activities amounted to $220.3 million in Q4 2025, which was down 3716.49% from -$402.9 million recorded in Q3 2025.
In the past 5 years, Regeneron Pharmaceuticals' Cash from Investing Activities registered a high of $647.5 million during Q1 2025, and its lowest value of -$2.4 billion during Q3 2021.
Over the past 5 years, Regeneron Pharmaceuticals' median Cash from Investing Activities value was -$526.8 million (recorded in 2023), while the average stood at -$772.6 million.
The largest annual percentage gain for Regeneron Pharmaceuticals' Cash from Investing Activities in the last 5 years was 62960.73% (2024), contrasted with its biggest fall of 61578.28% (2024).
Regeneron Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$2.0 billion in 2021, then grew by 7.7% to -$1.9 billion in 2022, then soared by 96.44% to -$66.2 million in 2023, then soared by 629.61% to $350.6 million in 2024, then crashed by 37.16% to $220.3 million in 2025.
Its Cash from Investing Activities stands at $220.3 million for Q4 2025, versus -$402.9 million for Q3 2025 and -$1.1 billion for Q2 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value